Nalaganje...
The role of targeted therapy in the management of patients with AML
Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration’s approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulat...
Shranjeno v:
| izdano v: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142552/ https://ncbi.nlm.nih.gov/pubmed/29222237 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|